Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis

Diabetes Therapy

Volumn 7, Issue 1, 2016, Pages 105-124

  Wilke, Thomas ^a   Mueller, Sabrina ^b   Groth, Antje ^a   Berg, Bjoern ^a   Fuchs, Andreas ^c   Sikirica, Mirko ^d   Logie, John ^e   Martin, Alan ^e   Maywald, Ulf ^c  

^a Hochschule Wismar   (Germany)

^b INGRESS Health HWM GmbH   (Germany)

^c AOK Plus   (Germany)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

GLP 1 receptor agonists; Non adherence; Non persistence; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE;

ARTICLE; COHORT ANALYSIS; GERMANY; INSULIN TREATMENT; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; UNITED KINGDOM;

EID: 84961789172     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0149-4     Document Type: Article

References (30)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228–36.
2. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104(1):1–52.
3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes—Langfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014. Available from http://www.dm-therapie.versorgungsleitlinien.de.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.
5. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19–28.
6. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–84.
7. Papaetis GS. Incretin-based therapies in prediabetes: current evidence and future perspectives. World J Diabetes. 2014;5(6):817–34.
8. de Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80(1):47–56.
9. Slabaugh SL, Xu Y, Stacy JN et al. Antidiabetic treatment patterns in a medicare advantage population in the United States. Drugs Aging. 2015. [Epub ahead of print].
10. Miller BR, Nguyen H, Hu CJ, Lin C, Nguyen QT. New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits. 2014;7(8):452–63.
11. Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2014. [Epub ahead of print].
12. Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015. [Epub ahead of print].
13. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther. 2014;31(12):1287–305.
14. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87.
15. Grimes RT, Bennett K, Tilson L, Usher C, Smith SM, Henman MC. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients. Br J Clin Pharmacol. 2014. [Epub ahead of print].
16. Wilke T, Groth A, Mueller S, et al. How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus. Eur J Health Econ. 2013;14(3):551–68.
17. Dirmaier J, Watzke B, Koch U, et al. Diabetes in primary care: prospective associations between depression, nonadherence and glycemic control. Psychother Psychosom. 2010;79(3):172–8.
18. Doggrell SA, Warot S. The association between the measurement of adherence to anti-diabetes medicine and the HbA1c. Int J Clin Pharm. 2014;36(3):488–97.
19. An J, Nichol MB. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013;51(10):879–87.
20. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.
21. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777–86.
22. Malmenäs M, Bouchard JR, Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg. Clin Ther. 2013;35(6):795–807.
23. Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119–33.
24. Ostenson CG, Matthaei S, Reaney M, et al. Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes. 2014;6:171–85.
25. WHO Collaborating Centre for Drug Statistics Methodology. (2013) Guidelines for ATC classification and DDD assignment. Oslo: 2014.
26. BAnz. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Exenatide. 2008. Available from https://www.g-ba.de/downloads/39-261-736/2008-10-16-AMR4-Exenatide_BAnz.pdf.
27. Ostenson CG, Matthaei S, Reaney M, et al. Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes. 2013;6:171–85.
28. Lund A, Knop FK, Visboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25(5):407–14.
29. Fabbian F, De Giorgi A, Monesi M, et al. All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used? Diab Vasc Dis Res. 2014. [Epub ahead of print].
30. Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Cederholm J. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register. Eur J Prev Cardiol. 2014;21(2):244–51.